IPP Bureau
Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy
By IPP Bureau - June 06, 2025
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
Sun Pharma discontinue development of SCD-044 drug after trial disappointment
By IPP Bureau - June 05, 2025
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
Bristol Myers Squibb and BioNTech sign up to $11 billion cancer bispecific antibody collaboration
By IPP Bureau - June 05, 2025
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Allarity announces enrolment of first patient in phase 2 clinical trial protocol of Stenoparib in advanced ovarian cancer
By IPP Bureau - June 05, 2025
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
UK MHRA approves aumolertinib to treat non-small cell lung cancer
By IPP Bureau - June 05, 2025
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Sanofi exercises license extension option to Nurix’s STAT6 program
By IPP Bureau - June 04, 2025
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Amyris expands precision fermentation line in Brazil
By IPP Bureau - June 04, 2025
Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
iNGENu CRO, Quantum BioPharma to launch Australian trial for chronic nociplastic pain in MCAS patients
By IPP Bureau - June 04, 2025
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Biocon gets approval for diabetes drug Liraglutide in India
By IPP Bureau - June 03, 2025
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
By IPP Bureau - June 02, 2025
Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)
Sigachi Industries FY25 revenue surges 25%, EBITDA 46%
By IPP Bureau - June 02, 2025
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
